Evaluation of pleural effusion sCD26 and DPP-IV as diagnostic biomarkers in lung disease
Loading...
Identifiers
Publication date
Advisors
Tutors
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Nature Publishing Group
Abstract
In this study, we measured ADA and DPP-IV enzymatic activity and sCD26 concentration in 150 pleural
effusion (PE) samples and tested for correlations between these and other cellular and biochemical
measures. We found that DPP-IV in particular might improve the specificity (but not the sensitivity) of the
ADA test for diagnosis of pulmonary tuberculosis, since half of the false ADA positive results in
non-tuberculous PE were also DPP-IV positive. A percentage of patients with malignant PE were sCD26 or
DPP-IV positive; however, some patients with benign PE also tested positive. As a pattern associated with
DPP-IV (but not the CD26 protein) was observed in PE, we searched for a finding that might increase the
value of these biomarkers for diagnosis of malignancy. The observed pattern was related to the presence of
leukocytes, as indicated by correlations with the cell count, and to a band of 180 kDa, detected by
immunoblotting
Description
Bibliographic citation
Sánchez-Otero, N., Rodríguez-Berrocal, F., de la Cadena, M. et al. Evaluation of pleural effusion sCD26 and DPP-IV as diagnostic biomarkers in lung disease. Sci Rep 4, 3999 (2015). https://doi.org/10.1038/srep03999
Relation
Has part
Has version
Is based on
Is part of
Is referenced by
Is version of
Requires
Publisher version
https://doi.org/10.1038/srep03999Sponsors
This research was partially supported by grants PS09-00405 and Research Intensification activity from the Fondo de Investigación Sanitaria (FIS) of the Instituto de Salud Carlos III (Spain) and funding from Xunta de Galicia and FEDER (CN 2011/024). We are grateful to the patients who participated and made the study possible
Rights
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareALike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/








